Participants:

Pr. Arne Ljungqvist (AL), Chairman Attending
Pr. Don Catlin (DC) Attending
Pr. Eduardo De Rose (EDR) Attending
Dr Jiri Dvorak (JD) Attending
Pr. Theodore Friedmann (TF) Attending
Pr. David Gerrard (DG) Attending
Pr. Luis Horta (LH) Attending
Pr. Per Wiik Johansen (PJ) Attending
Pr. Ichiro Kono (IK) Attending
Dr. Jean-Claude Mbanya (JCM) Attending
Prof. Timothy Noakes (TN) Attending
Dr. Babette Pluim (BP) Attending
Dr. Brian Sando (BS) Attending
Dr. Patrick Schamasch (PS) Attending
Dr Gary Wadler (GW) Attending
Dr. José Antonio Pascual (TP) Apologies

WADA Staff
Dr. Osquel Barroso (OB) Attending
Dr. Alain Garnier (AG) Attending
Dr. Irene Mazzoni (IM) Attending
Dr. Olivier Rabin (OR) Attending

Guest
Dr. Fabio Pigozzi (IUSM, University of Rome)

1. Welcome and Review of the Agenda
   - David Howman and AL welcome the Committee members.
   - The Agenda is approved.

2. Review of 2009 Prohibited List and recommendation to the Executive Committee
   - The 2009 Draft of the Prohibited List prepared by the List Committee is presented by GW. Most changes proposed are accepted by the HMR Committee. Some points are further discussed:
     i. The List Committee proposed to transfer the lengthy explanation on results management included in the Anabolic Androgenic Steroids and other sections to a
technical document. The HMR Committee approves the idea in principle but it will have to be reviewed by WADA’s Legal Department.

ii. The matter of T/E ratio is raised again but no decision is taken to change the present ratio of 6.

iii. Since Abbreviated Therapeutic Use Exemptions (ATUE) no longer exist in the revised 2009 Code, the List Committee proposed that inhaled beta2-agonists, for which an ATUE is currently required, will only need a Declaration of use in the future. The HMR Committee considers that beta2-agonists are widely used and that best medical practices recommend using glucocorticosteroids rather than beta2-agonists for asthma treatment. As a consequence, the HMR Committee decides that a full TUE should be requested for all beta2-agonists regardless of their route of administration according to the current International Standard for Therapeutic use exemption (IS-TUE). The requirement for a full TUE for beta-2-agonists is taken by a majority decision.

iv. The clarification proposed by the List Committee on what constitutes a legitimate use of intravenous infusions is slightly amended by the HMR Committee to make it clearer.

v. The issue of pseudoephedrine is discussed. GW explains that based on the results from WADA’s excretion studies, more data is needed to establish a cut-off threshold to distinguish between legitimate use and abuse of pseudoephedrine. The HMR Committee agrees that a supplementary study will be conducted.

vi. For glucocorticosteroids, the HMR Committee proposes that, the routes of administration that currently require an ATUE will need a full TUE in 2009, except by inhalation. This decision is based on data that indicate that these routes lead to high systemic level of the drug.

3. Review and recommendation for the 2008 research projects

- Members of the HM&R Committee responsible for organizing the peer review process and WADA staff present a summary of the evaluations from the external independent reviewers received in their field.
- A ranking of projects within each category is made, and 30 projects are selected (see appendix 1).
- For several projects, budgetary revisions are recommended.
- Two projects from one group were considered to present extensive overlap and therefore a unified project is recommended.
- One project was considered important but risky. Therefore, a pilot project of one year duration was recommended, with further evaluation of the outcomes at the end of the granting period.
- Three projects by different groups dealing with beta2-agonists were found to address very relevant as well as secondary issues. Therefore a collaborative project addressing relevant topics will be proposed to the 3 groups to optimize the chances of positive outcomes and optimize financial resources.
- One project was approved with the condition that the Final report from a previous project, due for sometime, be sent to WADA and approved.
- One project was favorably reviewed but the HMR Committee believed it was similar to a project funded in the past that was modestly successful. Therefore, it is proposed to send the project for further evaluation to 2 other experts in the field.
- Some suggestions are done to the WADA Science Department regarding the reviewing processing for future Call for Grants: 1) unify reporting by the HMR Committee members, 2) English will be the only language accepted for applications, to facilitate the reviewing process, 3) indicate which are follow-up projects and provide report of previous grants; 4) indicate if there are overlaps with previous grants.
4. Gene Doping Meeting Symposium
- TF summarizes the outcomes of the Gene Doping Symposium that took place in St-Petersburg, Russia, June 10-12 2008.
- It was concluded that the genetic techniques to detect gene manipulation as well as pharmacological doping will become more relevant.
- It was recommended to survey more the internet, as well as interact more with the pharmaceutical companies, health professionals, law enforcement and commercial authorities.
- The St-Petersburg Declaration on Gene Doping can be found in WADA’s website, in the ‘Science and Medicine’ page under ‘Gene Doping’.

5. Report from TUE Subcommittee
- DG gives an update on the TUE Subcommittee activities during 2008.
- The revised International Standard for TUE (IS-TUE) was submitted for the May meeting of the WADA Executive Committee. There were some discrepancies due to the different timelines of approval with the Draft of the Prohibited List which was circulated before the final approval of the IS-TUE but have been harmonized during the September List Committee meeting.
- The Medical information to assist TUE Committees is continuously updated and reviewed.
- A workshop on medical aspects of TUEs is planned for early 2009.
- TUEs reviews by WADA Lausanne office are done in a timely manner. TUE statistics are not a true reflection of international trends as several ADOs do not send the data to WADA.
- It is proposed that the TUE and List Committees work closer in the future. As a starting point, DG was invited to assist to the 2nd day of the List Committee meeting. It is suggested that the HMR Committee encourages more interaction between its subcommittees.
- Although members of the WADA TUE Working Group, including its Chair, were present in Beijing, there was no interaction with the IOC TUE Committee. Future collaboration between these groups was recommended.

6. Report from Laboratory Subcommittee
- LH gives an update on the Laboratory Subcommittee.
- There were no false positive reported in the PT program.
- All laboratories were re-accredited except for HFL in UK, because it no longer achieved the annual minimum number of samples.
- There have been significant improvements in the Documentation Packages.
- Some corrective actions were not completely satisfactory and therefore 3 Laboratory Directors were requested to provide explanations before the WADA Laboratory Committee.
- There was a site visit to the Ukraine laboratory is seeking accreditation.
- The Indonesian laboratory did no re-enter the probationary phase.
- The New Delhi laboratory has completed the probationary phase and will be recommended for accreditation.
- The Almaty laboratory has successfully completed the 4 Proficiency Testing rounds but Kazakhstan have yet to sign the UNESCO Convention.
- The Romanian laboratory has entered the probationary phase.
- The WADA Laboratory Committee closely followed the preparation of the Beijing accredited laboratory for the Olympic Games.
- The International Standard for Laboratories (ISL) was approved and came into effect in January 2008.
• The Technical Documents were reviewed and the new Technical Document on Measurement Uncertainty is being drafted.
• A MoU between ILAC and WADA has been signed.
• The Laboratory Committee recommended that all accredited laboratories procure themselves with the Certified Reference Materials available, especially those developed by NMI Australia with WADA’s support.
• It is recommended that the laboratories continue to monitor dietary supplements as part of research activities but it is clearly stated in the ISL that they cannot do routine contract testing of these products.

7. Working Group on Laboratory Accreditation
• OR summarizes the activities of the Working Group. The recommendations are:
  i. To identify the environment of the laboratory.
  ii. Quality of the results.
  iii. Research activities and sharing of knowledge.
• The candidate laboratories will be approached with a questionnaire.
• There will be an increase in the minimal number of samples to be analyzed, from 1,500 to 3,000; there will be a grace period of 2 years for already accredited labs to achieve this goal.
• The IRMS, EPO, hGH will be made mandatory for all laboratories.

8. Any Other Business
• B sample: there are discussions on whether a B sample is still necessary, since, due to improvements in analytical technical along the years, the probability that it will not match the A sample is almost null. It is proposed to write a Memorandum including a historical background, reasons for having a B sample, options and circulate it to stakeholders for their opinion.
• Nature article critical of WADA testing: WADA has submitted a letter to the Editor where the criticisms were addressed in general, while the Lausanne accredited laboratory’s response addressed IRMS and statistical issues.

12. Next meeting
• The next HMR Committee meeting is scheduled for September 3th-4th 2009. There may be an additional meeting day (September 2nd) which would gather all WADA Scientific Committees and Subcommittees.
• The meeting is adjourned.

Appendices
Appendix 1: table of recommended research projects for 2008.